Literature DB >> 31685473

No Amikacin, No Problem: a Successful Treatment Approach for Pediatric Otomastoiditis Due to Amikacin-Resistant Mycobacterium abscessus.

William J Richter1, Keira A Cohen2.   

Abstract

Pediatric otomastoiditis due to Mycobacterium abscessus can be a devastating infection that presents multiple treatment challenges. Van Wijk et al. report the use of a structured approach with a standardized regimen of intravenous (i.v.), topical, and oral antibiotics and surgical intervention for four pediatric patients with multidrug-resistant Mycobacterium abscessus otomastoiditis. Despite treatment-related adverse events, all four patients achieved sustained cure with this approach. This case series provides a framework for managing drug-resistant Mycobacterium abscessus otomastoiditis.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium abscessuszzm321990; pediatric otomastoiditis

Mesh:

Substances:

Year:  2019        PMID: 31685473      PMCID: PMC7187579          DOI: 10.1128/AAC.02023-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus.

Authors:  Amit Kaushik; Nicole C Ammerman; Olumide Martins; Nicole M Parrish; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Otomastoiditis caused by non-tuberculous mycobacteria: report of 16 cases, 3 with infection intracranially.

Authors:  L Lundman; H Edvardsson; K Ängeby
Journal:  J Laryngol Otol       Date:  2015-07       Impact factor: 1.469

Review 3.  Mycobacterium abscessus, an uncommon cause of chronic otitis media: a case report and literature review.

Authors:  Joris J Linmans; Robert J Stokroos; Catharina F M Linssen
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-09

4.  Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis.

Authors:  Floor van Wijk; Jérôme Waterval; Koen van Aerde; Stefanie S V Henriet; F J Anton Meijer; Lennaert C Borra; Rob E Aarnoutse; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

5.  Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease.

Authors:  Kenneth N Olivier; David J Weber; Ji-Hyun Lee; Allison Handler; Gail Tudor; Paul L Molina; Joseph Tomashefski; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2002-11-14       Impact factor: 21.405

6.  Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease.

Authors:  Won-Jung Koh; Byeong-Ho Jeong; Su-Young Kim; Kyeongman Jeon; Kyoung Un Park; Byung Woo Jhun; Hyun Lee; Hye Yun Park; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Seung-Heon Lee; Chang Ki Kim; Sung Jae Shin; Charles L Daley; Hojoong Kim; O Jung Kwon
Journal:  Clin Infect Dis       Date:  2016-11-10       Impact factor: 9.079

7.  Mycobacterium chelonae causing otitis media in an ear-nose-and-throat practice.

Authors:  P W Lowry; W R Jarvis; A D Oberle; L A Bland; R Silberman; J A Bocchini; H D Dean; J M Swenson; R J Wallace
Journal:  N Engl J Med       Date:  1988-10-13       Impact factor: 91.245

Review 8.  The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance.

Authors:  Sakshi Luthra; Anna Rominski; Peter Sander
Journal:  Front Microbiol       Date:  2018-09-12       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.